A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carboplatin/Taxol/Pembrolizumab in patients receiving Neoadjuvant Chemotherapy (NACT) followed by Pembrolizumab Maintenance with or without Olaparib